Post-Romanow pharmacare: last-dollar first...first-dollar lost?

Area of Science:

• Health policy
• Pharmaceutical economics
• Public health

Background:

• Canada's mixed public-private drug coverage leads to unequal access and rising costs.
• Provincial variations in pharmaceutical benefits are a long-standing issue.
• The 2002 Romanow Commission proposed a national standard for pharmacare.

Purpose of the Study:

• To analyze the implications of a proposed national "last-dollar" pharmacare model in Canada.
• To assess the potential impact on existing provincial drug coverage programs.
• To evaluate the risk of reduced first-dollar benefits for vulnerable populations.

Main Methods:

• Policy analysis of proposed pharmacare models.
• Comparative study of Canadian provincial drug coverage.
• Review of recommendations from the Romanow Commission.

Main Results:

• A "last-dollar" model covers drug costs after a high deductible, contrasting with existing "first-dollar" programs.
• There is a significant risk that provincial governments may reduce or eliminate current first-dollar benefits.
• This shift could inadvertently narrow pharmacare access for vulnerable groups.

Conclusions:

• While last-dollar pharmacare could expand public coverage, it may not be a complete solution.
• Careful policy design is needed to prevent the erosion of existing first-dollar benefits.
• Ensuring continued access to essential medications for all Canadians requires a balanced approach.